|
|
|
| The Value of Escitalopram Combined with Magnesium Valproate in the Treatment of Depression Patients |
| YANG Jian, LIU Zhe, FENG Yuhong |
| Department of Psychiatry, Yan'an University Xianyang Hospital, Xianyang Shaanxi 712000 |
|
|
|
|
Abstract 【Objective】 To explore the efficacy of escitalopram combined with magnesium valproate in the treatment of depression. 【Methods】 A total of 84 depression patients who were treated at Xianyang Hospital of Yan'an University were randomly divided into two groups, with 42 patients in each group.The control group was treated with oral escitalopram, while the observation group was treated with a combination of escitalopram and magnesium valproate. We compared the treatment efficacy, hamilton depression scale (HAMD) scores, hamilton anxiety scale (HAMA) scores, wisconsin card sorting test (WCST) scores, and levels of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) between two groups before and after treatment, as well as the occurrence of adverse reactions after treatment. 【Results】 The total effective rate of the observation group was 76.19%(32/42), significantly higher than the control group's 54.76%(23/42), and the difference was statistically significant (P<0.05); After treatment, the HAMD and HAMA scores of both groups were lower than before treatment (P<0.05), and the observation group was lower than the control group (P<0.05); After treatment, the levels of 5-HT and NE in both groups were higher than before treatment (P<0.05), and the observation group was higher than the control group (P<0.05); After treatment, the WCST scores in both groups were significantly better than before treatment (P<0.05), and the observation group was better than the control group (P<0.05); There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 Escitalopram combined with magnesium valproate can effectively alleviate depression and anxiety in patients with depression, improve cognitive function, and have good safety.
|
|
Received: 30 December 2022
|
|
|
|
|
|
[1] CHEN X H,TIAN C Z,MENG Z,et al. The therapeutic effect of wuling capsule on tinnitus patients with anxiety and depression[J].Asian J Surg,2022, 45(3):939-940.
[2] 陈倩倩, 许瑞智, 汪晓静,等. 有氧运动干预抑郁症缓解期患者认知功能的临床随机对照研究[J].中华精神科杂志, 2021, 54(1):25-30.
[3] SUN X,WANG Z,MIAO D T,et al. The Efficacy of Escitalopram Combined with Olanzapine in Depression:A Systematic Review and Meta-analysis[J].World J Int Tradit Western Med,2021, 7(5):24-35.
[4] 尹延明, 赵学利,周桦,等. 抗精神病药物联合小剂量丙戊酸镁在精神分裂症患者中的疗效观察及对BDNF、GDNF水平的影响研究[J].国际精神病学杂志, 2019, 46(1):96-98.
[5] 中华医学会精神病学分会. 中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志, 2001, 34(3):184-188.
[6] PEIXOTO M F,CESARETTI M,HOOD S D,et al. Effects of SSRI medication on heart rate and blood pressure in individuals with hypertension and depression[J].Clin Exp Hypertens, 2019, 41(5):428-433.
[7] BRUNONI A R,MOFFA A H,SAMPAIO-JUNIOR B,et al.Trial of electrical direct-current therapy versus escitalopram for depression[J].New Engl J Med,2017, 376(26):2523-2533.
[8] 王铭锐, 云婷婷, 符丽红,等. 小剂量喹硫平联合丙戊酸镁治疗双相情感障碍伴精神病性症状抑郁发作的效果及安全性观察[J].山东医药, 2022, 62(5):71-73.
[9] 徐丽丽, 王云甫, 王娜,等. 丙戊酸镁缓释片联合帕罗西汀治疗卒中后抑郁的临床效果[J].中国医药, 2017, 12(5):746-749.
[10] 石保青, 张晓冬, 张月芳,等. 米那普仑联合电针治疗对中度抑郁患者血清5-HT、多巴胺水平的影响[J].国际精神病学杂志, 2019, 46(4):84-86.
[11] 高小妹, 王青青, 侯萍,等. 度洛西汀联合丙戊酸镁缓释片治疗伴有疼痛的抑郁症疗效观察[J].神经疾病与精神卫生, 2013, 13(5):506-508.
[12] 杨玉仙, 夏曙, 张程亮. 抗惊厥药和抗抑郁药治疗癌症神经病理性疼痛的临床应用研究进展[J].药物流行病学杂志, 2019, 28(4):277-280.
[13] 夏庆润, 刘超, 杨魁,等. 小剂量丙戊酸镁对精神分裂症阳性症状病人认知功能及血清脑源性、胶质源性神经营养因子水平的影响[J].安徽医药, 2019, 23(10):2082-2086.
[14] 唐霞, 孔凡平. 丙戊酸镁缓释片联合帕罗西汀对老年脑卒中后抑郁患者抑郁症状及神经功能的影响[J].医学临床研究, 2017, 34(6):1186-1188.
[15] 敖小君, 朱丽莎, 王晓芳,等. 加兰他敏联合丙戊酸镁治疗阿尔茨海默病疗效及对患者血清CER、BDNF、miR-132水平的影响[J].中国药师, 2020, 23(2):303-306. |
|
|
|
2024, Vol. 41 
